Polymyxin B Administration Guidelines

Introduction to Polymyxin B Administration

• The American College of Clinical Pharmacology recommends administering polymyxin B with a loading dose of 2-2.5 mg/kg followed by maintenance dosing of 1.5-3 mg/kg/day divided into two daily intravenous doses, with no dose reduction required for renal impairment 1, 2

Loading Dose Protocol

• The Infectious Diseases Society of America suggests always initiating therapy with a loading dose of 2-2.5 mg/kg to rapidly achieve therapeutic plasma concentrations on the first day, regardless of renal function status 1, 2
• The loading dose must be given to all patients, including those with severe renal dysfunction or on continuous renal replacement therapy (CRRT) 1

Maintenance Dosing

• The American College of Clinical Pharmacology recommends administering 1.5-3 mg/kg/day divided into two doses (every 12 hours) as the standard maintenance regimen 1, 2
• For a 70 kg patient, the maintenance dose is 105-210 mg/day divided into two doses 1

Critical Renal Function Considerations

• The National Kidney Foundation states that polymyxin B does not require dose adjustment for renal impairment, which is the most important distinction from colistin and contradicts older FDA labeling 1, 3
• Do not reduce doses in patients with renal impairment - maintain standard dosing of 1.5-3 mg/kg/day even in severe renal dysfunction 1, 2
• No dose adjustment is necessary for patients on CRRT 1, 3

Combination Therapy Requirements

• The Infectious Diseases Society of America recommends using polymyxin B in combination therapy rather than monotherapy for carbapenem-resistant infections 2
• For ventilator-associated pneumonia (VAP) or hospital-acquired pneumonia (HAP) caused by carbapenem-resistant pathogens sensitive only to polymyxins, combine intravenous polymyxin B with adjunctive inhaled colistin (not inhaled polymyxin B) 4
• Consider combination with tigecycline or meropenem (extended infusion) for carbapenem-resistant Enterobacterales bloodstream infections 5

Nephrotoxicity Risk Management

• The American College of Clinical Pharmacology states that polymyxin B has significantly lower nephrotoxicity than colistin (11.8% vs 39.3%) 3, 2

Therapeutic Drug Monitoring

• The American College of Clinical Pharmacology recommends targeting a steady-state average concentration of approximately 3.35 mg/L 1, 2
• Optimal AUCss,24h target is 50-100 mg·h/L 2
• Therapeutic drug monitoring is encouraged to optimize dosing and minimize toxicity 1

Duration of Therapy

• The Infectious Diseases Society of America recommends a 7-day course of antimicrobial therapy for HAP/VAP 4
• For carbapenem-resistant Enterobacterales bloodstream infections, a 7-14 day course is recommended 5

Intrathecal Polymyxin B Dosing

Recommended Regimen for Patients > 2 Years

• Administer 50,000 units (≈ 5 mg) of polymyxin B intrathecally once daily for 3–4 days, then every other day for at least 2 weeks after cerebrospinal‑fluid cultures become negative, as reported in Clinical Infectious Diseases. 6

Polymyxin B Dosing and Clinical Use Guidelines

Recommended Maintenance Dosing

• For adult patients with multidrug‑resistant Gram‑negative infections, administer polymyxin B at 2.5–3.0 mg/kg per day, divided into two intravenous doses given every 12 hours. This regimen is considered the standard maintenance dose for the majority of patients. 7

Indications and Combination Therapy

• In infections caused by carbapenem‑resistant Enterobacterales (CRE), polymyxin B should be used in combination with either tigecycline or extended‑infusion meropenem, selected based on in‑vitro susceptibility results. Combination therapy is advised to improve microbiologic eradication and clinical outcomes. 8

Monitoring and Dose Optimization

• Therapeutic drug monitoring (TDM) of polymyxin B plasma concentrations is recommended to guide dose adjustments and achieve optimal pharmacodynamic targets, thereby enhancing efficacy while minimizing toxicity. 7

Setting and Expertise Requirements

• Polymyxin B use should be restricted to healthcare settings where there is a high prevalence of multidrug‑resistant Gram‑negative pathogens and where clinicians possess specific expertise in its dosing, monitoring, and safety management. 7

Need for Drug‑Level Guided Adjustments

• Drug‑level assessment and subsequent dose or interval adjustments are required to attain optimal therapeutic outcomes, especially given the drug’s inter‑patient pharmacokinetic variability. 7

Polymyxin B Dosing Guidelines (Evidence‑Based)

Loading Dose

Maintenance Dose

Hepatic Impairment

Therapeutic Drug Monitoring (TDM)

Combination Therapy

Dosing Conversion Reference

Polymyxin B Dosing and Clinical Use Guidelines

Loading Dose

• A loading dose of 2–2.5 mg/kg intravenously should be given on day 1 to rapidly achieve therapeutic plasma concentrations. 13

Maintenance Dosing and Infusion Strategy

• The recommended maintenance regimen is 1.5–3 mg/kg per day, divided into two equal doses administered every 12 hours. 13
• Continuous intravenous infusion can be used as an alternative to intermittent dosing. 13

Renal Function Considerations

• No dose reduction is required for patients with renal impairment, including those receiving continuous renal replacement therapy (CRRT). 13

Combination Therapy for Carbapenem‑Resistant Infections

• Polymyxin B should be used in combination therapy rather than as monotherapy for infections caused by carbapenem‑resistant organisms. [14][15]
• For carbapenem‑resistant Enterobacterales bloodstream infections, combine polymyxin B with tigecycline or extended‑infusion meropenem (1 g over 3 hours every 8 hours). 15
• For ventilator‑associated pneumonia due to carbapenem‑resistant pathogens, add inhaled colistin to intravenous polymyxin B (inhaled polymyxin B is not recommended). 14
• For Acinetobacter infections that are susceptible only to polymyxins, pair polymyxin B with another active antimicrobial whenever feasible. 14

Duration of Therapy

• Hospital‑acquired or ventilator‑associated pneumonia should be treated for 7 days. 14
• Carbapenem‑resistant Enterobacterales bloodstream infections require 7–14 days of therapy. 15
• Complicated urinary tract infections should receive 5–7 days of treatment. 15
• The exact duration should be individualized based on infection site, source‑control measures, patient comorbidities, and clinical response. 15

Polymyxin B Clinical Recommendations Based on Evidence

Maintenance Dosing

• The most commonly used maintenance regimen is 2.5–3.0 mg/kg per day administered as two equal intravenous doses (e.g., for an adult patient, approximately 105–210 mg/day)【16】.

Setting and Expertise Requirements

• Use of polymyxin B should be restricted to healthcare facilities with a high prevalence of multidrug‑resistant Gram‑negative pathogens and where clinicians possess specific expertise in polymyxin B dosing, therapeutic drug monitoring, and safety management【16】.

Combination Therapy

• Polymyxin B must be administered in combination with another active antimicrobial for infections caused by carbapenem‑resistant organisms【17】.
• For carbapenem‑resistant Enterobacterales bloodstream infections, combine polymyxin B with tigecycline or extended‑infusion meropenem (1 g over 3 h every 8 h) when the meropenem MIC is ≤ 8 mg/L for CRE or ≤ 32 mg/L for carbapenem‑resistant A. baumannii【17】.

Therapeutic Drug Monitoring (TDM)

• TDM is strongly encouraged to individualize dosing; target a steady‑state average concentration of ~3.35 mg/L and an AUC₀₋₂₄ of 50–100 mg·h/L to balance efficacy and toxicity【17】.
• Renal function should be monitored closely during therapy because nephrotoxicity, although lower than with colistin, remains dose‑dependent【17】.

Safety and Dosing Clarifications

• To avoid dosing errors, note that 1 mg of polymyxin B equals 10,000 units, whereas 1 million IU of colistin corresponds to 80 mg CMS (≈33 mg colistin base activity)【17】.
• Concurrent use of other nephrotoxic agents (e.g., aminoglycosides, NSAIDs, diuretics, ACE inhibitors/ARBs) should be avoided to minimize additive risk of kidney injury【17】.